Complete Response With Trametinib in Advanced Low-Grade Serous Ovarian Carcinoma: A Case Report
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A patient with recurrent low-grade serous ovarian carcinoma (LGSOC) achieved a complete response with trametinib, a MEK inhibitor. This case highlights potential efficacy of targeted therapy in advanced LGSOC.
Area Of Science
- Oncology
- Genetics
- Pharmacology
Background
- Low-grade serous ovarian carcinoma (LGSOC) presents unique challenges due to chemoresistance and poor prognosis.
- Standard treatment often involves platinum-based chemotherapy and cytoreduction, but recurrence is common.
Observation
- A 45-year-old female with stage III-C LGSOC experienced relapse after initial chemotherapy and cytoreduction.
- Hormonal therapy was ineffective, and chemotherapy was refused; bevacizumab provided 30 months of stabilization.
Findings
- Single-agent trametinib, a MEK inhibitor, induced a sustained complete response for over 36 months in recurrent LGSOC.
- This represents the first reported complete response to a MEK inhibitor outside clinical trials for recurrent LGSOC with unknown BRAF V600E mutation.
Implications
- Trametinib may offer a novel therapeutic option for patients with advanced or recurrent LGSOC, particularly those refractory to other treatments.
- Further investigation into MEK inhibitor efficacy in LGSOC, irrespective of BRAF mutation status, is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
